Puma Biotechnology Inc (PBYI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $401.70M
Last updated: Nov 17, 2026 at 11:06 AM ET
Puma Biotechnology Inc (PBYI) P/E Ratio & Valuation History
Puma Biotechnology (PBYI) trades at 15.0x trailing earnings and 1.6x sales. Its P/E of 15.0x is above its 5-year median of 9.9x. Its forward P/E is 3.5x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 328.6% higher over the next year.
| Multiple | Value |
|---|---|
| P/E (trailing) | 15.0x |
| Forward P/E | 3.5x |
| Price to sales | 1.6x |
| Price to book | 2.6x |
| EV/EBITDA | 9.2x |
| PEG | N/A |
Historical Medians
Against its 10-year medians, its P/S is 33.3% above 1.2x and its P/B is 60.6% below 6.6x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 15.0x | 9.9x | N/A |
| P/S | 1.6x | 0.7x | 1.2x |
| P/B | 2.6x | 3.3x | 6.6x |
Valuation History
Over the 4 of the 10 year ends shown that have a P/E, its P/E ranged from 3.9x in 2024 to 21.1x in 2022.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $5.95 | 9.2x | 1.3x | 2.4x |
| 2024 | $3.05 | 3.9x | 0.6x | 1.6x |
| 2023 | $4.33 | 7.0x | 0.9x | 3.9x |
| 2022 | $4.23 | 21.1x | 0.9x | 9.0x |
| 2021 | $3.04 | N/A | 0.5x | N/A |
| 2020 | $10.26 | N/A | 1.8x | N/A |
| 2019 | $8.75 | N/A | 1.2x | 19.6x |
| 2018 | $20.35 | N/A | 3.1x | 22.7x |
| 2017 | $98.85 | N/A | 133.8x | 69.6x |
| 2016 | $30.70 | N/A | N/A | 5.2x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About PBYI
What is PBYI's forward P/E ratio?
Puma Biotechnology has a forward P/E ratio of 3.5x.
Is PBYI stock overvalued?
GNG's valuation label for PBYI is Overvalued.
What is PBYI's price to sales ratio?
Puma Biotechnology has a price to sales ratio of 1.6x.
What is Puma Biotechnology's average P/E ratio over 5 years?
Puma Biotechnology's median P/E over the last 5 years is 9.9x, from 50 month-end values through Oct 2026.
PBYI pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors